Digital intelligence blog

Medtronic partners with Fitbit for diabetes tracking

Will integrate the health trackers into its CGM
mobile app

Medtronic is working with Fitbit to integrate health and activity tracking functions into the new version of its continuous glucose monitoring (CGM) mobile app.

The medical technology firm hopes its iPro2 myLog app will provide a simplified way for patients with type 2 diabetes to manage their condition by presenting their glucose and physical activity levels within a single app.

Medtronic said its tie-up with Fitbit would provide “meaningful insights into how exercise impacts glucose levels for more effective diabetes care management”.

Laura Stoltenberg, general manager of Non-Intensive Diabetes Therapies at Medtronic, said: "[There] has never been more important to increase the collaboration between healthcare and technology to simplify daily diabetes management for the 29 million patients living with type 2 diabetes in the US.

"By creating a connection between physical activity and glucose levels, our iPro2 myLog mobile app solution provides new tools and insights, so that physicians can optimise therapy and patients can better understand how to manage their diabetes.”

The aim is for the new version of the app, which is available for Apple and Android devices, to provide a better understanding of the impact exercise has on glucose levels, and the partners said MyLog would also make it easier for information to be shared with a patient's healthcare team.

Adam Pellegrini, vice president of digital health for Fitbit, said: "We believe the integration of wearable technology with professional diagnostic tools can provide a more accurate and actionable view of a patient's physical activity.

"By partnering with Medtronic, we are able to bring the power of Fitbit's automatic activity tracking together with continuous glucose monitoring, allowing patients and providers to have a more informed conversation."